Medtronic, Inc.

Deepak Ramesh Thakker

Eric Burright

Jennifer Heisel

Lisa Lynn Shafer

William Frederick Kaemmerer

Michael Eric Benz

Carl A Schu

Paul W Wacnik

Greg Stewart

Lothar Krinke

Eric Neal Burright

Carl A Shu

Jennifer M Heisel

Broad cerebrospinal fluid (CSF) distribution of an agent is achievable by delivering the agent in a liquid formulation to the CSF at flow rates less than 500 microliters per hour, such as between about 2 microliters per hour and about 100 microliters per hour.

Methods for distributing agents to areas of brain

Methods, agents and devices for treating a patient to reduce accumulation of certain proteins in the brain are described. Such proteins include amyloid beta (A&#x3b2;), and the methods, agents and devices are useful for reducing the accumulation of A&#x3b2;, which is a principal constituent of the plaques associated with such diseases as Alzheimer's disease (AD). Antibodies to A&#x3b2;, when delivered systemically or directly into the central nervous system, improve cognitive deficits in a transgenic mouse model of AD. However, unlike peripheral antibodies to A&#x3b2;, which increased cerebral vascular plaques and hemorrhages, direct central administration did not result in such an increase cerebral vascular plaques and hemorrhages.

Methods and device to neutralize soluble toxic agents in the brain

The present invention is directed to compositions methods and kits for regulation of gene therapies, including, without limitation, reversible gene therapies and allele-specific therapies.

Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity

Methods, agents and devices for treating a patient to reduce accumulation of certain proteins in the brain are described. Such proteins include A&#x3b2;, and the methods, agents and devices are useful for reducing the accumulation of A&#x3b2;, which is a principal constituent of the plaques associated with such diseases as Alzheimer's disease (AD). Antibodies to A&#x3b2;, when delivered systemically or directly into the central nervous system, improve cognitive deficits in a transgenic mouse model of AD. However, unlike peripheral of antibodies to A&#x3b2;, which increased cerebral vascular plaques and hemorrhages, direct central administration did not result in such an increase cerebral vascular plaques and hemorrhages.

Antibody complexes including anti-A&#x3b2; antibodies conjugated with a sialic acid-containing molecule show improved bioavailability with no significant adverse effects on binding to amyloid beta.

Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules

The present invention is directed to compositions, methods and kits for regulation of gene therapies for Huntington's Disease, including, without limitation, reversible gene therapies and allele-specific therapies.

The instant invention provides a method for improving efficiency of RNA delivery to cells. The method comprises applying a low strength electric field to the cells and then after a certain time period, administering the ribonucleic acid sequence to the cells. Devices, kits, and RNA molecules suitable for delivery and devices suitable for practicing the disclosed methods are also provided.

Methods and devices for improved efficiency of RNA delivery to cells

Disclosed herein are methods, sequences and nucleic acid molecules used to treat pain. Specifically, the methods and sequences include locally administering molecules that suppress the expression of amino acid sequences that encode for Na1.7 channels or that otherwise inhibit the function of Na1.7 channels. Local suppression of Na1.7 channel levels and/or function will occur in the peripheral sensory neurons of the dorsal root ganglia.

Suppression of SCN9A gene expression and/or function for the treatment of pain

The invention provides novel combination therapies for treating Huntington's disease which comprise a) BDNF or suitable fragments thereof and b) agents capable of causing inhibition of a gene responsible for the neurodegenerative disease. The invention provides nucleic acid sequences, methods, and systems suitable for applications of these combination therapies.

Growing community of inventors

Blaine, MN, United States of America

Deepak Ramesh Thakker